US/UK/Canada

Share

Contacts

  • Elos Medtech AB (publ)
    Torsgatan 5B, 411 04 Göteborg
    +46 10 - 171 20 00
    http://www.elosmedtech.com

    • Quotes

    “We will continue to collaborate with our present customers, but also increase our collaboration with technical partners”
    Soren Olesen, Dental Business Director, Elos Medtech
    “Keeping a close dialogue with our partners and maintaining a high level of competence has led to a product portfolio with the right focus – simple and innovative dental products for an open digital workflow.”
    Soren Olesen, Dental Business Director, Elos Medtech
    Elos Medtech is excited to highlight orthopaedics as one of the primary areas of focus and to execute on our market specific strategies. This is a natural step toward achieving our growth targets and capitalizing on our 2015 acquisition of Onyx Medical
    Jan Wahlström, CEO and President.
    Pick a time period -
    Tags ( Active)

    Elos Medtech and Klingel create a powerhouse in the CDMO market

    Elos Medtech is pleased to announce the successful conclusion of its acquisition of Klingel Holding GmbH (Klingel), marking a significant milestone in the company's strategic expansion. The acquisition, first disclosed on July 28, 2023, solidifies Elos Medtech's position as a global leader in Contract Manufacturing for the Medical Device market. The collaboration between Elos Medtech and Klingel creates a powerhouse of over 1500 employees spread across 13 sites in 6 countries. This combined force propels the newly formed entity into the top 10 global players in the Contract Development

    Change in number of shares and votes in Elos Medtech

    Elos Medtech AB (publ) (”Elos Medtech” or the ”Company”) has, as previously announced, carried out a rights issue of shares of series B. The issue of shares has resulted in changes in the number of shares and votes in Elos Medtech as follows: Prior to the issuance of new shares of series B, there were in total 8,068,000 shares in Elos Medtech, of which 1,099,740 shares of series A, corresponding to an equal number of votes, and 6,968,260 shares of series B, corresponding to 696,826 votes, corresponding to 1,796,566 votes in total. Through the rights issue, the number of shares of

    Elos Medtech’s application for de-listing has been approved

    Elos Medtech AB (publ)’s (“Elos Medtech” or the “Company”) application for de-listing has now been approved by Nasdaq Stockholm. The last day of trading in Elos Medtech’s shares on Nasdaq Stockholm will be 19 December 2023. As previously announced, Elos Medtech has applied for de-listing of the Company’s shares from Nasdaq Stockholm. Nasdaq Stockholm has now approved the application and resolved that the last day of trading will be 19 December 2023. For further information, please contact: Stefano Alfonsi, President and CEO, +44 772 04 98 342, email: stefano.alfonsi@elosmedtech.com

    Elos Medtech applies for de-listing from Nasdaq Stockholm

    The board of directors of Elos Medtech has today resolved to apply for de-listing of the Company’s shares from Nasdaq Stockholm as a result of TA Associates, through EM Intressenter AB (“EM Intressenter”), controlling more than 90 percent of the shares in Elos Medtech AB (publ) (“Elos Medtech” or the “Company”), today having initiated compulsory redemption of the remaining shares in the Company. EM Intressenter has informed the board of directors of Elos Medtech that EM Intressenter initiates compulsory redemption of the remaining shares in Elos Medtech and requested that the shares in

    EM Intressenter AB initiates compulsory redemption proceedings

    EM Intressenter AB (“EM Intressenter”), holding approximately 94.3 percent of the shares and approximately 83.6 percent of the votes in Elos Medtech (“Elos Medtech” or the “Company”), has today initiated compulsory redemption of the remaining shares in Elos Medtech. Elos Medtech will notify the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from the date of the notification, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to

    Resolutions from the EGM of Elos Medtech AB (publ)

    Elos Medtech AB (publ) (“Elos Medtech” or the “Company”) held an extraordinary general meeting on Monday 13 November 2023 in Gothenburg. Resolution on appointment of a special examinerShareholders representing 1,047,133 shares (corresponding to approximately 12.979 percent av the total number of shares in the Company) voted for the proposal to appoint a special examiner, which means that conditions for application of special examination to the Swedish Companies Registration Office are fulfilled. The time period for the examination shall be the period from 3 May 2023 until the time

    Elos Medtech announces final outcome of the rights issue

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Elos Medtech announces final outcome of the rights issue The subscription period for Elos Medtech AB (publ)’s (“Elos Medtech” or the “Company”)

    Elos Medtech publishes prospectus for the rights issue and updates timetable

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Elos Medtech publishes prospectus for the rights issue and updates timetable The prospectus for the rights issue of shares of series B  in Elos

    Elos Medtech Interim Report 1 January – 30 September, 2023

    July – September 2023 · Net sales for the third quarter amounted to SEK 251.2 (231.5) million, an increase of 8.5 percent compared to the same quarter last year. Net sales in local currencies increased by 4.3 percent. · Operating profit amounted to SEK 31.7 (37.7) million, corresponding to an operating margin of 12.6 (16.3) percent. · Profit after net financial items amounted to SEK 30.9 (29.0) million. Net financial items were positively affected by exchange rate differences of SEK 7.5 (-5.3) million and totaled SEK -0.8 (-8.7) million. · Cash flow from operating activities

    Notice to attend the extraordinary general meeting of Elos Medtech AB (publ)

    The shareholders of Elos Medtech AB (publ), reg. no. 556021-9650, headquartered in Gothenburg (“Elos Medtech” or the “Company”), are hereby invited to the extraordinary general meeting (the “EGM”) on Monday, 13 November 2023. The EGM will be held at 13:00 at Torsgatan 5B, 411 04 Gothenburg, Sweden. The meeting venue will open at 12:00 for registration. Registration of participants at the meeting ends when the meeting is called to order. Right to participation Shareholders who wish to participate in the proceedings of the EGM must: · be registered as shareholders in the register

    Regulatory approvals obtained for the Klingel Acquisition and the Rights Issue

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Regulatory approvals obtained for the Klingel Acquisition and the Rights Issue On 28 July 2023, Elos Medtech AB (publ) (“Elos Medtech” or the “

    Resolutions from the EGM of Elos Medtech AB (publ)

    Elos Medtech AB (publ) (“Elos Medtech” or the “Company”) held an extraordinary general meeting on Friday 15 September 2023 in Gothenburg. Amendment of the articles of association The general meeting resolved, in accordance with the board of directors’ proposal, to: 1. increase the limits for the minimum and maximum share capital so that the share capital in the Company shall be not less than SEK 176,487,500 and not more than SEK 705,950,000; 2. increase the limits for the minimum and maximum number of shares, so that the number of shares in the Company shall be not less than 28,

    Notice to attend the extraordinary general meeting of Elos Medtech AB (publ)

    The shareholders of Elos Medtech AB (publ), reg. no. 556021-9650, headquartered in Gothenburg (“Elos Medtech” or the “Company”), are hereby invited to the extraordinary general meeting (the “EGM”) on Friday, 15 September 2023. The EGM will be held at 14:00 at Torsgatan 5B, 411 04 Gothenburg, Sweden. The meeting venue will open at 13:00 for registration. Registration of participants at the meeting ends when the meeting is called to order. Right to participation Shareholders who wish to participate in the proceedings of the EGM must: · be registered as shareholders in the register

    Elos Medtech resolves on rights issue subject to approval of the general meeting

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE FURTHER REGISTRATION MEASURES. OTHER RESTRICTIONS ARE APPLICABLE. PLEASE SEE “IMPORTANT INFORMATION” AT THE END OF THE PRESS RELEASE. Elos Medtech AB (publ) (“Elos Medtech” or the “Company”), today announces that the board of directors has decided to carry out a new issue of shares

    Elos Medtech acquires Klingel Medical through a guaranteed rights issue

    Creating a leading European MedTech CDMO with the combination of Elos Medtech and Klingel Elos Medtech AB (publ) (“Elos Medtech”), a leading development and manufacturing partner for medical devices, today entered into an agreement to acquire Klingel Holding GmbH (“Klingel Medical Group” or “Klingel”) from IK Partners and management. Klingel, a leading contract development and manufacturing organization (CDMO) headquartered in Germany, will strengthen Elos Medtech’s position with extraordinary R&D capabilities and new technology expertise. Further, the acquisition will broaden the

    Elos Medtech Interim Report January 1 – June 30, 2023

    April – June 2023 · Net sales for the second quarter amounted to SEK 269.8 (233.1) million, an increase of 15.8 percent compared to the same quarter last year. Net sales in local currencies increased by 9.5 percent. · Operating profit amounted to SEK 30.1 (37.8) million, corresponding to an operating margin of 11.2 (16.2) percent. · Profit after net financial items amounted to SEK 13.7 (38.8) million. Net financial items were negatively affected by exchange rate differences of SEK -8.6 (3.6) million and totaled SEK -16.4 (1.1) million. · Cash flow from operating activities was

    Resolutions from Continued General Meeting of Elos Medtech AB (publ)

    Elos Medtech AB (publ) held a Continued General Meeting on Wednesday 28 June 2023 in Gothenburg. The Continued General Meeting resolved to discharge Stefano Alfonsi, Magnus René, Jan Wahlström and Jodie Gilmore from liability for the financial year 2022. A majority of the votes cast voted for discharge from liability, while shareholders representing 13.17 % of all shares in the company voted against discharge from liability for Lovisa Lander, Birker B. Bahnsen and Alexander Cicetti for the financial year 2022.Minutes from the Continued General Meeting together with complete

    Global Medtech Leader Elos Medtech Celebrates 100 Years of Innovation and Partnership

    Elos Medtech, a global provider of medical technology solutions, proudly announces a momentous achievement as it reaches the remarkable milestone of 100 years this June. Founded in June 1923 as a Swedish manufacturing enterprise that specialized in repairing forestry equipment, the company management soon realized the enormous potential of leveraging their precision engineering skills in an emerging medical technology market. The company embarked on a journey partnering with healthcare professionals, research institutions and industry experts worldwide. A collaboration with Professor

    Notice to attend the continued general meeting of Elos Medtech AB (publ)

    The shareholders of Elos Medtech AB (publ), corporate ID no. 556021-9650, headquartered in Gothenburg, are hereby invited to the continued general meeting on Wednesday, 28 June 2023. The continued general meeting will be held at 4:30 p.m. at Setterwalls Advokatbyrå, Sankt Eriksgatan 5, 411 05 Gothenburg, Sweden. The meeting venue will open at 3:30 p.m. for registration. Registration of participants at the continued general meeting ends when the meeting is called to order. The Board of Directors has resolved that shareholders shall also be able to exercise their voting rights at the

    Resolutions from Annual General Meeting of Elos Medtech AB (publ) 2023

    Elos Medtech AB (publ) held its Annual General Meeting (”AGM”) on Wednesday 3 May 2023 in Gothenburg. Adoption of income statements and balance sheets for 2022 The AGM adopted the income statements and balance sheets for the company and the group included in the annual report for the financial year 2022. Allocation of profits At the request of shareholders Thomas Öster, Inger Öster, Venova AB, Kent Molin, Lars Öster, Jonas Fridh, Lennart and Anna Nyberg and Fountainhead Real Estate AG (jointly the “Minority Owners”), representing 1,062,283 shares (more than one-tenth of all

    Elos Medtech Interim Report January 1 - March 31, 2023

    January – March 2023 · Net sales for the first quarter amounted to SEK 267.2 (194.5) million, an increase of 37.4 percent compared to the same quarter last year. Net sales in local currencies increased by 29.5 percent. · Operating profit amounted to SEK 44.4 (29.2) million, corresponding to an operating margin of 16.6 (15.0) percent. · Profit after net financial items amounted to SEK 30.8 (29.8) million. Net financial items were negatively affected by exchange rate differences of SEK -4.7 (0.8) million and totaled SEK -13.6 (0.6) million. · Cash flow from operating activities

    Elos Medtech signs agreement with global healthcare company to expand production capacity

    Elos Medtech signs agreement with global healthcare company to expand production capacity in China.  The annual value of the deal is approximately CNY 90 million by 2025. Elos Medtech will invest approximately CNY 50 million in the next 2 years. Elos Medtech has signed an amendment to an existing agreement with a global healthcare customer active in the fields of diabetes and other chronic diseases, to provide an additional CNY 90 million in annual production output by the end of 2025. The additional volume will be made by the production site in Tianjin for the Chinese market. Elos

    Elos Medtech publishes Annual Report and Sustainability Report 2022

    Elos Medtech AB's Annual Report (Swedish) and Sustainability Report for the fiscal year 2022 have today been published and are now available on the Group’s website, www.elosmedtech.com. The Annual Report 2022 can be found under IR/Financial Reports. The Sustainability Report 2022 is published under Who we are/Sustainability Responsibility. About Elos MedtechElos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The company operates from facilities in Sweden, Denmark, China, and

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media

    Twitter